Skip to main content
Signal8

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

$NVNOPress releaseMay 7, 2026, 8:05 AM ETRead the release

enVVeno Medical ended Q1 2026 with $24.9 million in cash and investments, providing a runway into Q3 2027 to support the TAVVE pivotal study. The company achieved a landmark FDA IDE approval for the TAVVE study, the first-ever FDA approval for a pivotal study of a non-surgical replacement venous valve.

Key figures

Revenue
0
Guidance
Cash resources sufficient to fund operations into Q3 2027; cash burn rate expected to increase to approx $4M-$5M per quarter in 2026 due to TAVVE study initiation
Revenue Yoy
0
Net loss
3800000
Cash burn
3300000
Cash and investments
24900000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    NVNO: enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System — AI Analysis | Signal8